|54.01||+0.7600||+1.43%||Vol 13.71M||1Y Perf 9.41%|
|Jan 25th, 2021 16:00 DELAYED|
|0.38 0.70%||- -|
|Target Price||63.85||Analyst Rating||Strong Buy 1.33|
|Potential %||18.22||Finscreener Ranking||★★★ 49.75|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★ 42.93|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★★★★ 59.68|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||☆ 23.91|
|Market Cap||141.75B||Earnings Rating||Buy|
|Price Range Ratio 52W %||62.04||Earnings Date||11th Feb 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th Feb 2021|
|Estimated EPS Next Report||0.53|
|EPS Growth Next 5 Years %||16.80|
|Avg. Weekly Volume||13.71M|
|Avg. Monthly Volume||12.57M|
|Avg. Quarterly Volume||10.50M|
Astrazeneca PLC (NYSE: AZN) stock closed at 54.01 per share at the end of the most recent trading day (a 1.43% change compared to the prior day closing price) with a volume of 13.74M shares and market capitalization of 141.75B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 64600 people. Astrazeneca PLC CEO is Pascal Soriot.
The one-year performance of Astrazeneca PLC stock is 9.41%, while year-to-date (YTD) performance is 8.04%. AZN stock has a five-year performance of 75.11%. Its 52-week range is between 36.15 and 64.94, which gives AZN stock a 52-week price range ratio of 62.04%
Astrazeneca PLC currently has a PE ratio of 55.30, a price-to-book (PB) ratio of 11.31, a price-to-sale (PS) ratio of 7.74, a price to cashflow ratio of 31.50, a PEG ratio of 2.32, a ROA of 3.92%, a ROC of 10.73% and a ROE of 19.75%. The company’s profit margin is 11.14%, its EBITDA margin is 32.00%, and its revenue ttm is $18.32 Billion , which makes it $6.98 revenue per share.
Of the last four earnings reports from Astrazeneca PLC, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.53 for the next earnings report. Astrazeneca PLC’s next earnings report date is 11th Feb 2021.
The consensus rating of Wall Street analysts for Astrazeneca PLC is Strong Buy (1.33), with a target price of $63.85, which is +18.22% compared to the current price. The earnings rating for Astrazeneca PLC stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Astrazeneca PLC has a dividend yield of 1.67% with a dividend per share of $0.90 and a payout ratio of 167.00%.
Astrazeneca PLC has a Buy technical analysis rating based on Technical Indicators (ADX : 11.91, ATR14 : 3.02, CCI20 : 195.36, Chaikin Money Flow : 733.89, MACD : 0.47, Money Flow Index : 64.54, ROC : 7.61, RSI : 70.62, STOCH (14,3) : 95.23, STOCH RSI : 1.00, UO : 62.74, Williams %R : -4.77), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Astrazeneca PLC in the last 12-months were: Michel Demare (Buy at a value of $102 382), Nazneen Rahman (Buy at a value of $39 698), Philip A J Broadley (Buy at a value of $99 888), Tony Mok (Buy at a value of $172 640)
Copyright (c) 2021. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.